Acer Therapeutics Inc. Banner Image

Acer Therapeutics Inc. has reached its limit for free report views

Work for Acer Therapeutics Inc.? Upgrade Your Profile and unlock all your annual reports.

Acer Therapeutics Inc.

  • Ticker ACER
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Acer Therapeutics Inc. Logo Image
  • 11-50 Employees
  • Based in Newton, Massachusetts
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrateMore) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.
Acer Therapeutics Inc.

Most Recent Annual Report

Acer Therapeutics Inc. MOST RECENT 2019 Form 10K

Report Locked. Acer Therapeutics Inc. has reached its limit for free report views.